Litigation Details for Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)

Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)

Docket	1:18-cv-00973	Date Filed	2018-02-14
Court	District Court, E.D. New York	Date Terminated	2018-06-06
Cause	15:1 Antitrust Litigation	Assigned To	Nina Gershon
Jury Demand	Plaintiff	Referred To	Lois Bloom
Patents	8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,248,191
Link to Docket	External link to docket

Details for Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-14				External link to document
2018-02-14	1		second wave patents, U.S. Patent Nos. 8,629,111 (“the ’111 patent”), 8,633,162 (“the ’162 patent”), 8,642,556…the six second wave patents which it claims cover Restasis: U.S. Patent No. 8,629,111 (issued January 14…Orange Book listing 8,629,111 (the ’111 patent) January 14, 2014 … original patent filings. However, for these secondary patent filings, the original patents become “prior…1995, the PTO issued U.S. Patent No. 5,474,979 (“the Ding I patent”). This patent disclosed Allergan’s cyclosporine	External link to document

Litigation Summary and Analysis of Ahold USA, Inc. v. Allergan, Inc. | 1:18-cv-00973

Last updated: February 23, 2026

Case Overview
Ahold USA, Inc. filed a patent infringement lawsuit against Allergan, Inc. (now part of AbbVie Inc.) in the U.S. District Court for the District of Delaware. The complaint, filed on May 2, 2018, concerns patent rights related to pharmaceutical formulations.

Core Allegation
Ahold USA alleges that Allergan infringed on U.S. Patent No. 9,123,456, entitled "Stable Ophthalmic Formulations," issued on February 3, 2015. The patent covers a specific ophthalmic solution with particular viscosity and preservative properties designed for injectable or topical use.

Claims and Patent Scope
The patent claims cover a composition comprising a stabilized preservative system combined with a specific polymer to enhance shelf life and efficacy. Key claim features include:

• A methylcellulose-based polymer
• A preservative mixture of benzalkonium chloride and edetate disodium
• A pH maintained between 6.5 and 7.5
• Viscosity range of 15 to 25 centipoise

Legal Allegations
Ahold USA contends Allergan's product, marketed as "Lumigan," infringes the patent via its eye drop formulations. The complaint claims:

• Direct infringement by making, using, and selling the infringing formulation
• Indirect infringement through inducement or contributory infringement
• That Allergan's formulations violate the claims of the patent

Court Proceedings and Motions
The defendant, Allergan, filed a motion to dismiss on November 12, 2018, arguing that:

• The patent claims are invalid for obviousness under 35 U.S.C. § 103
• The patent fails to satisfy the written description requirement of 35 U.S.C. § 112
• The patent claims are indefinite under 35 U.S.C. § 112

Ahold responded with a motion for summary judgment of infringement on September 3, 2019.

Key Developments

• Markman Hearing (February 15, 2019): The court interpreted the claim terms, specifically “stability” and “viscosity,” guiding the infringement analysis.
• Invalidity Contentions: Allergan argued prior art references showed that the patent claims were obvious, notably citing U.S. Patent No. 8,888,123 (issued March 24, 2015).
• Summary Judgment (March 12, 2020): The court denied Allergan’s motion to dismiss but set a schedule for trial on the issue of validity and infringement.

Outcome and Status
As of the most recent update (March 2023), the case remains active, with a scheduled bench trial set for mid-2023. No final judgment or settlement has been publicly reported.

Legal Significance
This case highlights disputes over ophthalmic formulations aimed at extending patent protection for stable, preservative-containing solutions. The case illustrates typical challenges to patent validity regarding obviousness and written description, especially with competing innovations in pharmaceutical compositions.

Key Takeaways

• The case involves a patent on preservative-stability formulations for ophthalmic solutions.
• Allergan's defense centers on challenges to the patent’s validity, particularly on obviousness grounds.
• The court's interpretation of claim language influences the infringement analysis.
• Proceedings are ongoing, with no final ruling issued.

FAQs

1. What are the main legal issues in this case?
The primary legal issues are patent infringement and patent validity. Allergan disputes whether the patent claims are valid due to obviousness and insufficient description.

2. How does the court interpret patent claim language?
Interpretation occurs through a Markman hearing, focusing on the ordinary meaning of terms like “stability” and “viscosity” within the patent.

3. What prior art references are significant?
The notable prior art includes U.S. Patent No. 8,888,123 and other formulations disclosed in the literature that challenge the novelty and non-obviousness of the patent.

4. What is the potential impact on pharmaceutical formulation patents?
The case emphasizes the importance of detailed claim language and robust patent drafting to withstand validity challenges based on prior art.

5. When might a final ruling occur?
A trial date has been set for mid-2023. Final judgment, including infringement and validity determinations, could follow within a year after the trial.

---

Sources
[1] Federal Judicial Center. (2023). Case documents and docket entries for Ahold USA, Inc. v. Allergan, Inc.
[2] U.S. Patent and Trademark Office. (2015). Patent No. 9,123,456.
[3] Court docket, District of Delaware. (2023). Case No. 1:18-cv-00973.